Eli Lilly News

Is artificial intelligence blowing a bubble? Probably not, but the rally is still risky. Nvidia has become the undisputed leader in a stock market powered by AI hopes. Valuations are lofty for both the U.S.

Lilly expects to launch Mounjaro, its blockbuster diabetes drug and a wildly popular obesity treatment, in India as early as next year, CEO David Ricks told Reuters on Wednesday. The market opportunity is huge in the world's most populous country, which has high obesity rates, especially among women, and the second-highest number of people with type-2 diabetes globally. Indian drugmakers are making their own versions of such drugs, while illegal versions are also sold online. «We're open to any way to reach more patients as long as it makes sense for the company and we can supply the market,» Ricks said when asked if Lilly was open to authorised generic versions of drugs containing tirzepatide, the active ingredient in popular diabetes and weight-loss drugs.

FOX News medical contributor Dr. Marc Siegel discusses how prepared hospital E.R.s are to treat kids and the side effects of weight loss drugs on 'The Big Money Show.'

In late January, Eli Lilly (NYSE:LLY) weight-loss drugs helped the Indianapolis-based drugmaker replace Tesla (NASDAQ:TSLA) from the Magnificent 7.

In a market dominated by the 'Magnificent 7' group of mega-cap tech stocks, investors often overlook other market leaders poised for significant growth.

₹1,514.4 crore in 2022, and it is projected to reach ₹2,762.7 crore by 2028, demonstrating a noteworthy compound annual growth rate, or CAGR, of 10.6% during the period from 2023 to 2028. While India’s diabetes care drugs market size is estimated at $1.7 billion in 2024, and is expected to reach $2.01 billion by 2029, growing at a CAGR of 3.5% during 2024-2029, according to Mordor Intelligence, a market intelligence and advisory firm. The company is also reported to be in dialogue with multinational corporation Eli Lilly for its GLP-1 class of drugs.

Drugmakers kicked off 2024 by raising the list prices for Ozempic, Mounjaro and dozens of other widely used medicines. Companies including Novo Nordisk, the maker of Ozempic, and Eli Lilly, which sells Mounjaro, raised list prices on 775 brand-name drugs during the first half of January, according to an analysis for The Wall Street Journal by 46brooklyn Research, a nonprofit drug-pricing analytics group. The drugmakers raised prices of their medicines by a median of 4.5%, though the prices of some drugs rose by around 10% or higher, according to the research group.

Advisors searching forinvesting themes in 2024 may want to try AI, health care innovation and new supply chains, a BlackRock strategist says.

Eli Lilly has launched a unique website to connect U.S. patients seeking obesity treatment to doctors, dieticians and its new weight-loss drug, Zepbound

By David Carnevali

Wall Street is drifting following signals the job market remains solid, though it may be a touch too strong

Eli Lilly & Co. (NYSE:LLY) added 4.3% Wednesday, marking its strongest performance in two months, following Bank of America's designation of the drugmaker as its top pick among large cap biopharmaceutical companies for 2024.

Obesity drugs like Wegovy and Zepbound are capturing the attention of celebrities and showing promising results in helping people shed pounds

By Ankika Biswas, Khushi Singh and Bansari Mayur Kamdar

how to do it in a manner that could make them a staple of cancer care. That’s reflected in pharma companies’ sudden deep commitment to the space. In addition to AbbVie’s acquisition, other deals this year include Pfizer’s proposed $43 billion buyout of Seagen, Merck & Co’s $4 billion tie-up with Daiichi Sankyo, and a series of smaller investments from Bristol-Myers Squibb and Eli Lilly & Company.

(Reuters) — Eli Lilly (NYSE:LLY)'s recently approved obesity drug Zepbound is now available in U.S. pharmacies and could be available to some insured customers at $550 per month or half of the list price, the U.S. drugmaker said on Tuesday.

(Reuters) — Eli Lilly (NYSE:LLY), on Monday, gave Point Biopharma Global shareholders more time to sell their stock to the drugmaker amid low participation since the offer price was below the current stock price of the radiopharma developer.

Pfizer shares sank Friday when the drugmaker announced that it was abandoning a twice-daily obesity treatment after more than half the patients in a clinical trial stopped taking it

By Ludwig Burger and Noele Illien

Eli Lilly announced that the drug Jaypirca has been given second approval by the US Food and Drug Administration (FDA), on Friday, December 1. The drug is used to treat a form of blood cancer.

By Khushi Mandowara and Christy Santhosh